SUBCUTANEOUS VS INTRAVENOUS ADMINISTRATION OF TRASTUZUMAB IN HER2+BREAST CANCER PATIENTS: A MACEDONIAN COST-MINIMIZATION ANALYSIS

被引：2
|
作者：
Nestorovska, A. [1 ]
Naumoska, Z. [1 ]
Grozdanova, A. [1 ]
Stoleski, D. [2 ]
Ivanovska, A. [2 ]
Risteski, M. [3 ]
Vasev, N. [3 ]
Ismaili, I. [3 ]
Stefanovski, P. [4 ]
Dimovski, A. [1 ]
Suturkova, L. [1 ]
Sterjev, Z. [5 ]
机构：
[1] ISPOR Republ Macedonia Reg Chapter, Skopje, Macedonia
[2] DOOEL, Roche Macedonia, Skopje, Macedonia
[3] Univ Clin Radiotherapy & Oncol, Skopje, Macedonia
[4] Clin Hosp, Bitola, Macedonia
[5] UKIM Skopje, Fac Pharm, Skopje, Macedonia
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.1205
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN188
引用
收藏
页码：A463 / A463
页数：1
相关论文
共 50 条
  • [31] Subcutaneous versus intravenous administration of Trastuzumab: a minimization cost analysis with real world data from a reference cancer centre in Peru
    Otoya, Iris
    Valdiviezo, Natalia
    Roque, Katia
    Morante, Zaida
    Vidaurre, Tatiana
    Neciosup, Silvia P.
    Calderon, Monica J.
    Gomez, Henry L.
    ECANCERMEDICALSCIENCE, 2024, 18
  • [32] Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients
    Farolfi, Alberto
    Silimbani, Paolo
    Gallegati, Davide
    Petracci, Elisabetta
    Schirone, Alessio
    Altini, Mattia
    Masini, Carla
    ONCOTARGET, 2017, 8 (46) : 81343 - 81349
  • [33] BUDGET IMPACT AND COST MINIMIZATION ANALYSIS OF PHESGO ® (TRASTUZUMAB plus PERTUZUMAB SC) FOR THE TREATMENT OF HER2+BREAST CANCER IN THE CHILEAN PUBLIC HEALTH SYSTEM
    Rojas, R.
    Velasquez, M.
    Jana, N.
    Arriagada, L.
    Arenillas, S.
    Esquivel, C.
    Mendoza, C.
    Gejman, C.
    VALUE IN HEALTH, 2023, 26 (12) : S93 - S93
  • [34] A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer
    Dent, S.
    Ammendolea, C.
    Christofides, A.
    Edwards, S.
    Incekol, D.
    Pourmirza, B.
    Kfoury, S.
    Poirier, B.
    CURRENT ONCOLOGY, 2019, 26 (01) : E70 - E80
  • [35] COST-MINIMIZATION ANALYSIS OF ORAL VS. INTRAVENOUS FLUDARABINE (BENEFLUR®) IN SPAIN
    Delgado, J.
    Febrer, L.
    Nieves, D.
    Pinol, C.
    Brosa, M.
    VALUE IN HEALTH, 2008, 11 (06) : A635 - A635
  • [36] Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study
    Pivot, X.
    Spano, J. P.
    Espie, M.
    Cottu, P.
    Jouannaud, C.
    Pottier, V.
    Moreau, L.
    Extra, J. M.
    Lortholary, A.
    Rivera, P.
    Spaeth, D.
    Attar-Rabia, H.
    Benkanoun, C.
    Dima-Martinez, L.
    Esposito, N.
    Gligorov, J.
    EUROPEAN JOURNAL OF CANCER, 2017, 82 : 230 - 236
  • [37] Pre-specified interim analysis in a prospective, randomized phase II trial of trastuzumab vs trastuzumab plus NeuVax to prevent breast cancer recurrence in HER2+breast cancer patients
    Peace, Kaitlin M.
    Litton, Jennifer K.
    Murthy, Rashmi
    Vreeland, Timothy J.
    Hale, Diane F.
    Jackson, Doreen O.
    Berry, John S.
    Trappey, Alfred F.
    Herbert, Garth S.
    Clifton, Guy T.
    Hardin, Mark O.
    Peoples, George E.
    Mittendorf, Elizabeth A.
    CANCER RESEARCH, 2017, 77
  • [38] Impact of subcutaneous versus intravenous administration of pertuzumab and trastuzumab (PH) for the treatment of HER2-positive breast cancer in Montenegro
    Saric, N. Cicmil
    Lekic, S.
    Lakicevic, J.
    Todorovic, V.
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : S72 - S72
  • [39] Physician perceptions to use of trastuzumab in HER2+breast cancer in India
    Ramanjinappa, N.
    Agarwal, J.
    Upveja, K. H.
    ANNALS OF ONCOLOGY, 2022, 33 : S1437 - S1437
  • [40] Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study
    Pivot, Xavier
    Gligorov, Joseph
    Mueller, Volkmar
    Barrett-Lee, Peter
    Verma, Sunil
    Knoop, Ann
    Curigliano, Giuseppe
    Semiglazov, Vladimir
    Lopez-Vivanco, Guillermo
    Jenkins, Valerie
    Scotto, Nana
    Osborne, Stuart
    Fallowfield, Lesley
    LANCET ONCOLOGY, 2013, 14 (10): : 962 - 970
12345